Boehringer Ingelheim, a global leader in animal health, and MabGenesis, a private biopharmaceutical company headquartered in Yokohama, Japan, announce that they have entered into a collaboration to discover and develop novel monoclonal antibodies for potential canine therapeutic treatments. Under the agreement, MabGenesis will apply its unique platform to the discovery of first-in-class candidate antibodies against targets of interest selected by Boehringer Ingelheim. Boehringer Ingelheim will have the right to develop and commercialize products resulting from the collaboration. Terms of the agreement were not disclosed.
